6] deficiency significantly reduces the activities of aspartate aminotransferase
and alanine aminotransferase
in blood (Cheney et al.
5 mg/dL CO2 31 mmol/L 18-27 mmol/L Aspartate aminotransferase
3669 U/L 15-40 U/L Alanine aminotransferase
676 U/L 27-42 U/L Alkaline phosphatase 150 U/L 92-336 U/L 7-Glutamyl transpeptidase 10 U/L 14-35 U/L
Clinical studies have shown that a once-daily oral dose of REVOVIR not only reduces the amount of HBV DNA, but also normalises alanine aminotransferase
(ALT) levels in patients experiencing deterioration in liver function caused by chronic hepatitis B.
The drug has proven an effective inhibitor of virus replication and has indicated improvements in the increase of alanine aminotransferase
(ALT) and overall liver health.
A total of 36 patients were enrolled in the study, of which 31 (86%) had discontinued bosentan, 2 (6%) had discontinued sitaxsentan and 3 (8%) had discontinued both bosentan and sitaxsentan, sequentially, due to serum aminotransferase
Levels of C reactive protein, aminotransferases
, blood glucose, creatinine, urea nitrogen, and electrolytes were within the normal range.
0 g/dL Aspartate aminotransferase
202 [mu]/L 32 [mu]/L Alanine aminotransferase
198 [mu]/L 30 [mu]/L Alkaline phosphatase 541 [mu]/L 110 [mu]/L [gamma]-Glutamyl transferase 409 [mu]/L 62 [mu]/L Prothrombin time 25 seconds 11 seconds Total bilirubin 2.
In post-marketing experience, elevations of liver aminotransferases
(ALT, AST) have been reported with Letairis use.
Three weeks later, aminotransferases
continued to rise, with an AST level of 103 U/L and an ALT level of 184 U/L.
can often be increased by as much as 50 times the upper reference limit in acute viral, ischemic, and toxic hepatitis, whereas in alcoholic hepatitis the increases are generally <10-fold.
When an additional nine patients with chronic HCV infection and normal levels of aminotransferases
were added to the study, a test for serum CK-18 fragments could detect fibrosis at stage 2 or higher with 100% sensitivity and 68% specificity at a cutoff value of 221.
Asymptomatic elevation of serum aminotransferases
occurs in 25% of those treated.
Letairis can cause elevation of liver aminotransferases
(ALT and AST) to at least three times the upper limit of normal (ULN).
Chronological development of elevated aminotransferases
in a nonalcoholic population.
Compared with 758 IRAS subjects who did not develop type 2 diabetes, both of the aminotransferases
were associated with a significantly elevated risk for the development of diabetes--with odds ratios of 1.